Non-small cell lung cancer patients whose tumor cells had an abnormal ALK gene fared better if treated with crizotinib, a targeted therapy, than with traditional chemotherapy. Median progression-free survival was 7.7 months in the crizotinib group and three months in the chemotherapy group. Patients treated with crizotinib also reported a better quality of life than those treated with standard chemotherapy.
Fuente : http://www.eurekalert.org/pub_releases/2013-06/dci...
Fuente : http://www.eurekalert.org/pub_releases/2013-06/dci...